相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Chronic Active Epstein-Barr Virus Infection: The Elucidation of the Pathophysiology and the Development of Therapeutic Methods
Ayako Arai
MICROORGANISMS (2021)
Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial
Jingshi Wang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis
Camille Keenan et al.
FRONTIERS IN IMMUNOLOGY (2021)
Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome
Eduardo Huarte et al.
FRONTIERS IN PHARMACOLOGY (2021)
JAK inhibition for murine HLH requires complete blockade of IFN-γ signaling and is limited by toxicity of JAK2 inhibition
Vandana Chaturvedi et al.
BLOOD (2021)
Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia
Lisa M. Niswander et al.
HAEMATOLOGICA (2021)
A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis
Qing Zhang et al.
HAEMATOLOGICA (2021)
Salvage therapy with dose-escalating ruxolitinib as a bridge to allogeneic stem cell transplantation for refractory hemophagocytic lymphohistiocytosis
Yanmin Zhao et al.
BONE MARROW TRANSPLANTATION (2020)
Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis
F. Locatelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation
Lauren K. Meyer et al.
BLOOD (2020)
The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis
Sakshi Bami et al.
PEDIATRIC BLOOD & CANCER (2020)
IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome
Etienne Dufranc et al.
CRITICAL CARE (2020)
Efficacy of ruxolitinib in subcutaneous panniculitis-like T-cell lymphoma and hemophagocytic lymphohistiocytosis
Romain Levy et al.
BLOOD ADVANCES (2020)
Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis
Sabrin Albeituni et al.
BLOOD (2019)
Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial
Asra Ahmed et al.
LANCET HAEMATOLOGY (2019)
Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib
Scott R. Goldsmith et al.
BLOOD ADVANCES (2019)
Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A second experience
Inuk Zandvakili et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure
Yang Y. Ding et al.
HAEMATOLOGICA (2018)
Primary Epstein-Barr virus infection
Samantha K. Dunmire et al.
JOURNAL OF CLINICAL VIROLOGY (2018)
Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure
Yang Y. Ding et al.
HAEMATOLOGICA (2018)
Epstein-Barr Virus and Hemophagocytic Lymphohistiocytosis
Rebecca A. Marsh
FRONTIERS IN IMMUNOLOGY (2018)
Hematopoietic Stem Cell Transplantation for the Treatment of Epstein-Barr Virus-Associated T- or NK-Cell Lymphoproliferative Diseases and Associated Disorders
Akihisa Sawada et al.
FRONTIERS IN PEDIATRICS (2018)
Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A single patient experience
Jessica Slostad et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition
Scott W. Canna et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study
Elisabet Bergsten et al.
BLOOD (2017)
Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis
Larisa Broglie et al.
BLOOD ADVANCES (2017)
Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis
Rupali Das et al.
BLOOD (2016)
Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice
Sophia Maschalidi et al.
BLOOD (2016)
A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)
Mignon L. Loh et al.
PEDIATRIC BLOOD & CANCER (2015)
Current diagnosis and management of infectious mononucleosis
Evridiki K. Vouloumanou et al.
CURRENT OPINION IN HEMATOLOGY (2012)
Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol
Helena Trottestam et al.
BLOOD (2011)
HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis
Jan-Inge Henter et al.
PEDIATRIC BLOOD & CANCER (2007)
分享论文
